Mutations in KRAS correspond to nearly 30–60% of all carrier cases of colorectal cancer, to about 25–30% of pulmonary adenocarcinomas, and it is estimated that there is an alarming figure of around 90% among pancreatic cancers [53,54,55]. This evidence concerns the gene KRAS and colorectal cancer.